Boston Partners Grows Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Boston Partners increased their stake in Halozyme Therapeutics by 2.0%, holding approximately 416,325 shares valued at $26.16 million, with other investors also modifying their positions significantly in the company.
• In August, CEO Helen Torley sold 20,000 shares at $63.51 each, reducing her ownership by 2.65% to approximately 733,719 shares, valued over $46.5 million.
• Halozyme Therapeutics reported a better-than-expected quarterly earnings with an EPS of $1.54, exceeding analysts' estimates, while revenue increased by 40.8% year-over-year, totaling $325.72 million.

Boston Partners boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 416,325 shares of the biopharmaceutical company's stock after acquiring an additional 8,341 shares during the quarter. Boston Partners owned about 0.34% of Halozyme Therapeutics worth $26,165,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in HALO. Raymond James Financial Inc. acquired a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $21,838,000. CreativeOne Wealth LLC raised its stake in shares of Halozyme Therapeutics by 1.6% during the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after buying an additional 294 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $691,000. Marshall Wace LLP purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $212,000. Finally, Canada Pension Plan Investment Board raised its stake in shares of Halozyme Therapeutics by 77.8% during the 4th quarter. Canada Pension Plan Investment Board now owns 178,200 shares of the biopharmaceutical company's stock worth $8,520,000 after buying an additional 78,000 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

NASDAQ HALO traded up $1.15 during mid-day trading on Wednesday, hitting $71.13. The stock had a trading volume of 1,891,343 shares, compared to its average volume of 1,984,340. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $71.21. The company has a market cap of $8.32 billion, a price-to-earnings ratio of 16.28, a P/E/G ratio of 0.38 and a beta of 1.17. The company has a 50 day simple moving average of $58.02 and a 200 day simple moving average of $58.53. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. HC Wainwright increased their target price on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. JMP Securities increased their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. Finally, Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price for the company. in a research note on Tuesday, May 13th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $67.11.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 80,000 shares of company stock worth $4,532,600 over the last ninety days. Company insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.